Results 101 to 110 of about 18,821 (231)

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor

, 2018
Background Reticulated platelets are associated with impaired antiplatelet response to irreversibly acting P2Y12-receptor inhibitors. However, the impact of reticluated platelets (RP) on the reversibly acting injectable P2Y12-receptor ...
Christian Valina, Nikolaus Löffelhardt, Valina, Christian Marc, Kambis Mashayekhi, Mashayekhi, Kambis, Hochholzer, Willibald, Willibald Hochholzer, Christian Stratz, Neumann, Franz-Josef, Nührenberg, Thomas G., Dietmar Trenk, Thomas Nührenberg, Miroslaw Ferenc, Franz-Josef Neumann, Löffelhardt, Nikolaus, Ferenc, Miroslaw, Trenk, Dietmar, Stratz, Christian   +17 more
core   +1 more source

P2Y12 Receptor on the Verge of a Neuroinflammatory Breakdown [PDF]

, 2014
In the CNS, neuroinflammation occurring during pathologies as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) is the consequence of an intricate interplay orchestrated by various cell phenotypes.
Susanna Amadio, Alberto Savio Carrubba, Cinzia Volonté, Chiara Parisi, Savina Apolloni, Cinzia Montilli   +5 more
core   +1 more source

De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review

Chinese Medical Journal, 2019
. Objective:. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI).
Ya-Ling Han, Yuan-Yuan Ji
doaj   +1 more source

Investigator‐Led Research to Improve the Diagnostic Assessment of Platelet Function Disorders: Reflections on the Challenges and Rewards

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Investigator‐led research and quality improvement initiatives have led to important improvements in the diagnostic assessment of platelet function disorders (PFD). Methods Personal reflections were used to summarize our contributions to knowledge on PFD diagnostic assessment, pathogenesis, and bleeding risks.
Catherine P. M. Hayward
wiley   +1 more source

Differential endosomal sorting of a novel P2Y12 purinoreceptor mutant

, 2013
P2Y12 receptor internalization and recycling play an essential role in ADP-induced platelet activation. Recently, we identified a patient with a mild bleeding disorder carrying a heterozygous mutation of P2Y12 (P341A) whose P2Y12 receptor recycling was ...
Mundell, Stuart J, Cunningham, Margaret R, Cooke, Alexandra E, Nisar, Shaista P, Emery, Elizabeth D   +4 more
core   +1 more source

Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

Российский кардиологический журнал, 2019
The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled
S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin   +24 more
doaj   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

The future of P2Y12 receptor antagonists

, 2015
Platelet P2Y12 inhibitors have become a central component of the treatment strategy for patients with atherothrombosis due to the importance of platelet P2Y12 receptors in arterial thrombosis.
Thomas, Mark R; id_orcid, Storey, Robert F   +1 more
core   +1 more source

Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients

Neurology International, 2015
The specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms.
Ping Li, Haris Kamal, Melissa Baxter, Bijal K. Mehta   +3 more
doaj   +1 more source